B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative (DBCOND0081965)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05453500	Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia	Beta-D-Glucose Cortisone Cyclophosphamide Daunorubicin Doxorubicin Etoposide Prednisone Rituximab Tafasitamab Vincristine	treatment	2	recruiting
NCT02003222	Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia	Asparaginase Escherichia coli Beta-D-Glucose Blinatumomab Cortisone Cyclophosphamide Cytarabine Daunorubicin Dexamethasone Etoposide Mercaptopurine Methopterin Methotrexate Muromonab Pegaspargase Prednisone Rituximab Sulfate ion Vincristine	treatment	3	active_not_recruiting
NCT03488225	Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia	Calcium Cortisone Cyclophosphamide Cytarabine Dexamethasone Doxorubicin Inotuzumab ozogamicin Leucovorin Levoleucovorin Mercaptopurine Methopterin Methotrexate Ofatumumab Prednisone Rituximab Sulfate ion Vincristine	treatment	2	terminated
NCT02484430	Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia	Sapanisertib	treatment	2	active_not_recruiting
NCT01371630	Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia	Blinatumomab Cyclophosphamide Cytarabine Dexamethasone Inotuzumab ozogamicin Mercaptopurine Methotrexate Prednisone Rituximab Vincristine	treatment	1 / 2	recruiting
NCT03739814	Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia	Blinatumomab Inotuzumab ozogamicin Muromonab	treatment	2	recruiting